| gout |
220 |
| serum |
220 |
| synovial fluid |
220 |
| urate |
220 |
| interleukin-17f |
148 |
| polymorphism |
148 |
| rheumatoid arthritis |
148, 225 |
| meta-analysis |
148, 130 |
| cytokines |
123 |
| fibromyalgia |
123, 196 |
| oxidative stress |
123 |
| oxidized-low-density lipoprotein |
123 |
| pain |
123 |
| breast cancer |
141 |
| prevalence |
141 |
| survival |
141 |
| systemic rheumatic diseases |
141 |
| autoantibodies |
157 |
| organ damage |
157 |
| systemic lupus erythematous |
157 |
| bone mineral density |
130 |
| fracture |
130 |
| osteoporosis |
130 |
| sarcoidosis |
130 |
| anxiety |
186 |
| burnout |
186 |
| depression |
186 |
| fibromyalgia syndrome |
186 |
| perceived social support |
186 |
| genotype |
166 |
| human leukocyte antigen-b*27 |
166 |
| human leukocyte antigen system |
166 |
| protective allelic groups |
166 |
| spondyloarthropathies |
166 |
| accelerated nodulosis |
225 |
| anti-tumor necrosis factor drugs |
225 |
| methotrexate |
225 |
| familial mediterranean fever |
204 |
| speckle tracking |
204 |
| strain echocardiography |
204 |
| tei index |
204 |
| leeds assessment of neuropathic symptoms and signs |
196 |
| neuropathic pain |
196 |
| paindetect scale |
196 |
| cyclophosphamide |
233 |
| hearing loss |
233 |
| immunoglobulin g4-related disease |
233 |
| recurrent otitis media |
233 |
| rituximab |
233 |
| leptospirosis |
229 |
| renal failure |
229 |
| vasculitis |
229 |
| weil’s disease |
229 |
| behçet’s disease |
211 |
| etiology |
211 |
| mitochondrial deoxyribonucleic acid |
211 |
| single nucleotide polymorphism |
211 |
| cardiovascular risk |
176 |
| gout stages |
176 |
| obesity |
176 |
